Apotex sells European operations across five countries to Aurobindo

By zaymalz malz

Toronto-based Apotex, the largest producer of generic drugs in Canada, has agreed to sell its operations spanning five different European countries to Hydebrad-headquartered pharmaceutical manufacturing firm Aurobindo.

The deal, valued at €74mn (CAD$114mn), will see Aurobindo acquiring Apotex’s commercial operations across Poland, the Czech Republic, Spain, Belgium and the Netherlands, significantly bolstering its European presence.

See also:

“Acquiring Apotex' businesses in these key five countries will allow us to further expand our product offering, including OTC medicines in the Netherlands, and considerably strengthen our position in Eastern Europe,” said Venugopalan Muralidharan, Senior Vice President of European Operations, Aurobindo. 

Meanwhile, the sale will allow Apotex to focus its attention more readily across its core markets in the Americas.

“This is a positive move for our organization and enables us to further accelerate our efforts to drive additional growth in the Americas, while also creating manufacturing capacity to meet growing demand,” said Jeff Watson, President & Chief Operating Officer, Apotex.

As part of the deal, Apotex has agreed to a manufacturing and supply arrangement to support the transitional period that will occur as a result of these changes.


Featured Articles

JPMorgan Chase: Committed to supporting the next generation

JPMorgan has unveiled a host of new and expanded philanthropic activities totalling US$3.5 million to support the development of apprenticeship programmes

How efficient digital ecosystems became business critical

During this unprecedented era of rapid digital transformation, establishing a well-functioning ecosystem stands to benefit both employees and customers

Mastercard: Supporting clients at a time of rapid evolution

Mastercard has announced a significant expansion of its consulting business with the launch of new practices dedicated to both AI and economics

Why Ceridian has boldly rebranded to Dayforce

Human Capital

McKinsey’s eight lessons in leadership for aspiring CEOs

Leadership & Strategy

KPMG: The biggest challenges facing global CEOs in 2023

Leadership & Strategy